Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04925973 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Tofacitinib for Hospitalized Acute Severe Ulcerative Colitis Management

Study acronym: TRIUMPH
StatusActive, Not Recruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated October 24, 2023 (before its estimated December 2023 completion). Its status may not reflect the trial's current state.

Record History

  1. Primary completion date: Jun 2022 to Dec 2023 Trial status: Recruiting to Active, Not Recruiting · Enrollment target: estimated 26 to confirmed 24 · Completion date: Jun 2023 to Dec 2023 · 1 morev2 Show 4 more changesShow less
    • Trial status: Recruiting to Active, Not Recruiting
    • Enrollment target: estimated 26 to confirmed 24
    • Completion date: Jun 2023 to Dec 2023
    • Site details revised
  2. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The TRIUMPH study was designed to build on the existing literature by studying the efficacy of tofacitinib in hospitalized patients with acute severe ulcerative colitis. This trial will provide evidence for a possible new indication for the use of tofacitinib.
Trial Details
NCT Number NCT04925973
Lead Sponsor McMaster University
Collaborators: University of Manitoba, University of British Columbia, McGill University, University of Alberta
Conditions Ulcerative Colitis Acute
Enrollment 24 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov